



**Request for Proposal for an
Independent Medical Education Grant**

Request Summary	
Therapeutic Area	Neurofibromatosis Type 1 Plexiform Neurofibroma (NF1-PN)
Target Audience	Academic and community medical oncologists, neuro-oncologists, neurologists, surgical oncologists, neurosurgeons, advanced practice providers, and other healthcare providers who care for patients with NF1-PN.
Grant Type	Independent medical education (IME), including accredited IME (CME)
Program Format	Grand Rounds; didactic, interactive, and/or case-based learning methods; face-to-face, virtual-hybrid, virtual, enduring, and/or innovative educational formats.
Budget	No greater than \$200,000
Date of Request	October 22, 2024
Proposal Due Date	November 15, 2024
Submission Instructions	Complete proposals should contain a letter of request on organization letterhead, budget, needs assessment, learning objectives, program agenda, audience generation plan, and outcomes assessment plan. Submit complete applications using the SpringWorks Therapeutics, Inc., grant portal. More information may be found here .
Contact Information	SpringWorks Therapeutics Inc., Grants: grants@springworkstx.com

This Request for Proposal (“RFP”) may contain proprietary information that is confidential to SpringWorks Therapeutics, Inc. No part of this RFP or its attachments may be reproduced, in whole or in part, unless specifically required by the medical education provider for internal use in responding to the solicitation. Unauthorized disclosure of the RFP or its contents or failure to observe other specific requirements contained herein will result in disqualification from further consideration. No representations or warranties are made concerning the completeness or accuracy of the information contained in this RFP. All proposals, presentations, and supporting materials submitted in this solicitation will be treated with confidentiality.

PROCEDURES AND RULES

1.1 Purpose of the Request for Proposal (RFP)

SpringWorks Therapeutics (SpringWorks) is a commercial-stage biopharmaceutical company that applies a precision medicine approach to developing and delivering life-changing medicines.

We support medical education grants to educate healthcare providers across the multidisciplinary team to advance medical care and scientific research for patients with severe rare diseases and cancer.

The purpose of this request for proposal (RFP) for an independent medical education (IME) grant is to request and review grant proposals on the topic of neurofibromatosis type 1 plexiform neurofibroma (NF1-PN). This RFP describes SpringWorks' high-level requirements, the process for submission, and the details required.

We will evaluate IME grant requests that are independent of commercial bias and non-promotional. IME grants may be requested to support various activities, including live events, web-based education, and enduring materials.

1.2 RFP Selection Process and Dates

This section describes the basic steps such as RFP issuance and response.

Selection Criteria

Grant requests will be reviewed and funded based on responses to this RFP and the following criteria:

- The scientific and clinical understanding of the therapeutic area and experience launching IME programs in similar therapeutics areas, including severe rare diseases and cancer.
- Transparency of the proposed IME program, including clarity on the program format, learning objectives, program audience generation, budget, program agenda, program promotion, and outcomes assessment.
- Infrastructure and experience creating IME programs in face-to-face, virtual-hybrid, or virtual formats, including innovative methods to educate healthcare providers.
- Experience collaborating with scientific, medical, or patient organizations in IME programs
- Compliance with relevant laws, regulations, guidance, and professional standards relating to accredited independent medical education (CME) programs, including the Accreditation Council for Continuing Medical Education (ACCME™) *Standards for Integrity and Independence in Accredited Continuing Education*.

1.3 Contact Information

Any questions related to this RFP should be emailed to grants@springworkstx.com

1.4 General Conditions

RFP is Not a Contract

This RFP is not a contract offer. Responding to this RFP neither commits SpringWorks to award a contract to any medical education provider, even if all requirements stated in this RFP are met. SpringWorks reserves the right to cancel this RFP response process at any time.

Costs of RFP Response

All costs incurred directly or indirectly in the preparation of all materials, presentations, demonstrations, or other components related to the submission of your RFP response and follow-up evaluation are the responsibility of your company.

1.5 Compliance Guidelines

SpringWorks Therapeutics follows regulatory policies outlined by the Office of Inspector General (OIG) Compliance Guidelines, the Food and Drug Administration's (FDA) guidance regarding industry-supported scientific and educational activities, and the Accreditation Council for Continuing Medical Education (ACCME™). Under federal and state laws, SpringWorks Therapeutics must track and disclose certain expenditures directed to healthcare providers under the Centers for Medicare & Medicaid Services (CMC), National Physician Payment Transparency Program ("Sunshine Act" or "Open Payments") as applicable for payments or transfers of value to physicians or US-based teaching hospitals. External funding by SpringWorks Therapeutics is not provided as an incentive to recommend or prescribe a SpringWorks Therapeutics product.

Please consider how your program fits within established laws, regulations, and guidelines before submitting a request.

REQUEST FOR PROPOSAL, SCOPE

2.1 RFP Description and Requirements

The purpose of this request for proposal (RFP) for an independent medical education (IME) grant is to request and review grant proposals in the areas of NF1-PN. The complete proposal in response to this RFP should include the following:

- Letter of request on organization letterhead
- Program budget
- Needs assessment
- Learning objectives
- Program agenda
- Audience generation plan
- Outcomes assessment plan

Proposals that are incomplete or lacking one or more of the required items will not be considered.

2.2 Therapeutic Area Background

NF1 is a rare genetic disorder, with an incidence of approximately 1:2500, caused by loss-of-function mutations in the *NF1* gene, which encodes for the tumor suppressor protein neurofibromin.¹⁻³ Loss of functional neurofibromin results in persistent activation of the mitogen-activated protein kinase (MAPK) pathway, which plays a pivotal role in cell differentiation, proliferation, and survival.³⁻⁵ Overactivation of the MAPK pathway in patients with NF1 results in a predisposition for tumor development, particularly in the peripheral and central nervous systems.⁶ Nonmalignant nerve sheath tumors called plexiform neurofibromas (PNs) are a common clinical manifestation of NF1, occurring in approximately 30-50% of children and adults with the genetic disorder.^{7,8} NF1-PNs often cause debilitating morbidity, including pain, disfigurement, compression of internal organs, impaired physical function, and impaired quality of life.⁷⁻⁹ Malignant transformation may occur, and malignant peripheral nerve sheath tumors, which are aggressive sarcomas with poor prognosis, occur in up to 16% of patients with NF1.¹⁰⁻¹³ Limited treatment options are available for patients with NF1-PN. Inhibition of MAPK kinase (MEK) has emerged as a promising treatment strategy¹⁴, and the MEK inhibitor selumetinib is approved for patients aged 2 to 17 years with symptomatic, inoperable NF1-PN.¹⁵ Currently, there are no approved system therapies for adults with NF1-PN.

2.3 Educational Needs

SpringWorks has identified the following areas of educational interest and healthcare provider practice gaps in the therapeutic area of NF1-PN:

- Multidisciplinary team decision-making, referral, and management for pediatric and adult patients with neurofibromatosis type 1 plexiform neurofibromas (NF1-PN)
- The patient journey of adults with NF1-PN, including symptoms experienced by adults with NF1-PN, and the current challenges for adults with NF1-PN and healthcare

providers (physicians, advanced practice providers, nurses, care coordinators, etc.), including unmet needs

- Clinical trial outcomes, primary/secondary endpoints, response rate, patient-reported outcomes, adverse events, and safety/tolerability of system therapies for patients with NF1-PN
- Clinical practice recommendations for systemic therapy utilization for pediatric and adult patients with NF1-PN
- AE management and supportive care of pediatric and adult patients with NF1-PN treated with systemic therapies

2.4 References

1. Ejerskov C, Farholt S, Nielsen FSK, et al. Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study. *Oncol Ther.* 2023;11(1):97-110.
2. Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. *Int J Mol Sci.* 2021;22(11):5850.
3. Yap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited - from bench to bedside. *Oncotarget.* 2014;5(15):5873-5892.
4. Borrie SC, Brems H, Legius E, Bagni C. Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways. *Annu Rev Genomics Hum Genet.* 2017;18:115-142.
5. Harder A. MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions. *Biomark Res.* 2021;9(1):26.
6. Klesse LJ, Jordan JT, Radtke HB, et al. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. *Oncologist.* 2020;25(7):e1109-e1116.
7. Miller DT, Freedenberg D, Schorry E, et al. Health Supervision for Children With Neurofibromatosis Type 1. *Pediatrics.* 2019;143(5):e20190660.
8. Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. *J Pediatr.* 2012;160(3):461-467.
9. Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review. *Adolesc Health Med Ther.* 2021;12:55-66.
10. Evans DG, Baser ME, McGaughan J, Sharif S, Howard E, and Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet.* 2002;39(5):311-314.
11. Higham CS, Dombi E, Rogiers A, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. *Neuro Oncol.* 2018;20(6):818-825.
12. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. *Hum Pathol.* 2017;67:1-10.
13. Uusitalo E, Rantanen M, Kallionpaa RA, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. *J Clin Oncol.* 2016;34(17):1978-1986.

14. Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. *BMC Cancer*. 2023;23:553.
15. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. *N Engl J Med*. 2020;382:1430-42.